Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setrusumab in adult osteogenesis imperfecta
NCT03118570Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Sep 2017
- Primary completion
- Oct 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of setrusumab in osteogenesis imperfecta (OI), sponsored by Ultragenyx Pharmaceutical Inc.. Started Sep 2017; status: completed.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT03118570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118570.